Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102660 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT01102660 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 172 participants.
The verdict
NCT01102660, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.
Interventions
- DRUG Placebo
- DRUG Naproxen
- DRUG PH-797804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102660
The ClinicalTrials.gov registry entry for NCT01102660 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01102660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102660 about?
NCT01102660 is a clinical study titled "Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee". PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.
What is the current status of trial NCT01102660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2010-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01102660?
The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), PH-797804 (DRUG).
Who is sponsoring clinical trial NCT01102660?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.